Corrigendum to: Pulsed Focused Ultrasound Pretreatment Improves Mesenchymal Stromal Cell Efficacy in Preventing and Rescuing Established Acute Kidney Injury in Mice: Pulsed Focused Ultrasound-Induced MSC Homing Improves AKI (STEM CELLS, (2015), 33, 4, (1241-1253), 10.1002/stem.1965);Pulsed focused ultrasound pretreatment improves mesenchymal stromal cell efficacy in preventing and rescuing established acute kidney injury in mice

Stem Cells

Volumn 33, Issue 4, 2015, Pages 1241-1253

  Burks, Scott R ^a,b   Nguyen, Ben A ^b   Tebebi, Pamela A ^a,c   Kim, Saejeong J ^a   Bresler, Michele N ^a   Ziadloo, Ali ^a   Street, Jonathan M ^d   Yuen, Peter S T ^d   Star, Robert A ^d   Frank, Joseph A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c Catholic University of America   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acute kidney injury; Cellular therapy; Cisplatin; Kidney; Mesenchymal stromal cells; Renal; Renal failure; Stem cell transplantation

Indexed keywords

CISPLATIN; INTERLEUKIN 10;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DEATH; CELL HOMING; CELL REGENERATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PULSED FOCUSED ULTRASOUND; SURVIVAL RATE; ULTRASOUND THERAPY; ACUTE KIDNEY INJURY; ANIMAL; C3H MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME; ULTRASOUND;

ANIMALIA; MUS;

ACUTE KIDNEY INJURY; ANIMALS; FEMALE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C3H; TREATMENT OUTCOME; ULTRASONIC WAVES;

EID: 84925615277     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.3149     Document Type: Erratum

References (66)

1. Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. Kidney Int 2006; 70: 1120-1126.
2. Li PK, Burdmann EA, Mehta RL,. Acute kidney injury: Acute kidney injury-Global health alert. Nat Rev Nephrol 2013; 9: 133-135.
3. Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin J Am Soc Nephrol 2006; 1: 43-51.
4. Star RA,. Treatment of acute renal failure. Kidney Int 1998; 54: 1817-1831.
5. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336: 828-834.
6. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55: 2423-2432.
7. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36: 767-774.
8. Bi B, Schmitt R, Israilova M, et al. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007; 18: 2486-2496.
9. Togel FE, Westenfelder C,. Mesenchymal stem cells: A new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183.
10. Wise AF, Ricardo SD,. Mesenchymal stem cells in kidney inflammation and repair. Nephrology (Carlton) 2012; 17: 1-10.
11. Caplan AI, Correa D,. The MSC: An injury drugstore. Cell Stem Cell 2011; 9: 11-15.
12. Schrepfer S, Deuse T, Reichenspurner H, et al. Stem cell transplantation: The lung barrier. Transplant Proc 2007; 39: 573-576.
13. Moghadasali R, Azarnia M, Hajinasrollah M, et al. Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy 2014; 16: 734-749.
14. Ittrich H, Lange C, Togel F, et al. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: Detection and monitoring at 3T. J Magn Reson Imaging 2007; 25: 1179-1191.
15. Karp JM, Leng Teo GS,. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009; 4: 206-216.
16. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667-679.
17. Harting MT, Jimenez F, Xue H, et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009; 110: 1189-1197.
18. Kang SK, Shin IS, Ko MS, et al. Journey of mesenchymal stem cells for homing: Strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int 2012; 2012: 342968.
19. Tempany CM, McDannold NJ, Hynynen K, et al. Focused ultrasound surgery in oncology: Overview and principles. Radiology 2011; 259: 39-56.
20. Hancock HA, Smith LH, Cuesta J, et al. Investigations into pulsed high-intensity focused ultrasound-enhanced delivery: Preliminary evidence for a novel mechanism. Ultrasound Med Biol 2009; 35: 1722-1736.
21. Ziadloo A, Burks SR, Gold EM, et al. Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. Stem Cells 2012; 30: 1216-1227.
22. Burks SR, Ziadloo A, Hancock HA, et al. Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS One 2011; 6: e24730.
23. Burks SR, Ziadloo A, Nguyuen BA, et al. Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can increased through repeated applications. Stem Cells 2013; 31: 2551-2560.
24. Goldstein RS, Mayor GH,. Minireview. The nephrotoxicity of cisplatin. Life Sci 1983; 32: 685-690.
25. Yuan L, Wu MJ, Sun HY, et al. VEGF-modified human embryonic mesenchymal stem cell implantation enhances protection against cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2011; 300: F207-218.
26. Imai N, Kaur T, Rosenberg ME, et al. Cellular therapy of kidney diseases. Semin Dial 2009; 22: 629-635.
27. Zhu XY, Lerman A, Lerman LO,. Concise review: Mesenchymal stem cell treatment for ischemic kidney disease. Stem Cells 2013; 31: 1731-1736.
28. Yuen PS, Dunn SR, Miyaji T, et al. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004; 286: F1116-1119.
29. Pelte CH, Chawla LS,. Novel therapeutic targets for prevention and therapy of sepsis associated acute kidney injury. Curr Drug Targets 2009; 10: 1205-1211.
30. Yalavarthy R, Edelstein CL,. Therapeutic and predictive targets of AKI. Clin Nephrol 2008; 70: 453-463.
31. Morigi M, Introna M, Imberti B, et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26: 2075-2082.
32. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692.
33. Gheisari Y, Azadmanesh K, Ahmadbeigi N, et al. Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury. Stem Cells Dev 2012; 21: 2969-2980.
34. Sarkar D, Spencer JA, Phillips JA, et al. Engineered cell homing. Blood 2011; 118: e184-191.
35. Alkins R, Burgess A, Ganguly M, et al. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res 2013; 73: 1892-1899.
36. Burgess A, Ayala-Grosso CA, Ganguly M, et al. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS One 2011; 6: e27877.
37. Ghanem A, Steingen C, Brenig F, et al. Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction. J Mol Cell Cardiol 2009; 47: 411-418.
38. Tang HL, Wang ZG, Li Q, et al. Targeted delivery of bone mesenchymal stem cells by ultrasound destruction of microbubbles promotes kidney recovery in acute kidney injury. Ultrasound Med Biol 2012; 38: 661-669.
39. Zen K, Okigaki M, Hosokawa Y, et al. Myocardium-targeted delivery of endothelial progenitor cells by ultrasound-mediated microbubble destruction improves cardiac function via an angiogenic response. J Mol Cell Cardiol 2006; 40: 799-809.
40. Zhong S, Shu S, Wang Z, et al. Enhanced homing of mesenchymal stem cells to the ischemic myocardium by ultrasound-targeted microbubble destruction. Ultrasonics 2012; 52: 281-286.
41. Cantaluppi V, Biancone L, Quercia A, et al. Rationale of mesenchymal stem cell therapy in kidney injury. Am J Kidney Dis 2013; 61: 300-309.
42. Milwid JM, Ichimura T, Li M, et al. Secreted factors from bone marrow stromal cells upregulate IL-10 and reverse acute kidney injury. Stem Cells Int 2012; 2012: 392050.
43. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
44. Imberti B, Morigi M, Benigni A,. Potential of mesenchymal stem cells in the repair of tubular injury. Kidney Int Suppl 2011; 1: 90-93.
45. Nguan CY, Guan Q, Gleave ME, et al. Promotion of cell proliferation by clusterin in the renal tissue repair phase after ischemia-reperfusion injury. Am J Physiol Renal Physiol 2014; 306: F724-733.
46. Rota C, Imberti B, Pozzobon M, et al. Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 2012; 21: 1911-1923.
47. Ye Y, Wang B, Jiang X, et al. Proliferative capacity of stem/progenitor-like cells in the kidney may associate with the outcome of patients with acute tubular necrosis. Hum Pathol 2011; 42: 1132-1141.
48. Dong X, Swaminathan S, Bachman LA, et al. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007; 71: 619-628.
49. Okusa MD, Li L,. Dendritic cells in acute kidney injury: Cues from the microenvironment. Trans Am Clin Climatol Assoc 2012; 123: 54-62; discussion 62-53.
50. Molitoris BA,. Therapeutic translation in acute kidney injury: The epithelial/endothelial axis. J Clin Invest 2014; 124: 2355-2363.
51. Li L, Huang L, Ye H, et al. Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury. J Clin Invest 2012; 122: 3931-3942.
52. Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stem cells. Cell Death Diff 2014; 21: 216-225.
53. Singh-Jasuja H, Thiolat A, Ribon M, et al. The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology 2013; 218: 28-39.
54. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626-1635.
55. Okusa MD, Molitoris BA, Palevsky PM, et al. Design of clinical trials in acute kidney injury: A report from an NIDDK workshop-Prevention trials. Clin J Am Soc Nephrol 2012; 7: 851-855.
56. Gigliotti JC, Huang L, Ye H, et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013; 24: 1451-1460.
57. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626-1635.
58. Zhuo W, Liao L, Fu Y, et al. Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats. Transplant Proc 2013; 45: 503-510.
59. Behr L, Hekmati M, Fromont G, et al. Intra renal arterial injection of autologous mesenchymal stem cells in an ovine model in the postischemic kidney. Nephron Physiol 2007; 107: 65-76.
60. Ramesh G, Reeves WB,. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-842.
61. Wise AF, Williams TM, Kiewiet MB, et al. Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia/reperfusion injury. Am J Physiol Renal Physiol 2014; 306: F1222-F1235.
62. Duijvestein M, Wildenberg ME, Welling MM, et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558.
63. Kavanagh DP, Robinson J, Kalia N,. Mesenchymal stem cell priming: Fine-tuning adhesion and function. Stem Cell Rev 2014; 10: 587-599.
64. Huang J, Zhang Z, Guo J, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res 2010; 106: 1753-1762.
65. Komatsu K, Honmou O, Suzuki J, et al. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res 2010; 1334: 84-92.
66. Zhang L, Li K, Liu X, et al. Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats. Stem Cells Dev 2013; 22: 3074-3086.